

PROGRAMMA DI USO TERAPEUTICO CANAKINUMAB, ILARIS®

“Managed Access Program (MAP) to provide access to canakinumab treatment of cytokine release syndrome (CRS) in patients with COVID-19-induced pneumonia”

Di seguito si riportano i riferimenti a cui far pervenire le richieste:

map.italy@novartis.com / raffaella.guarisco@novartis.com (dott.ssa Raffaella Guarisco Cluster Medical Manager)